In the HR-negative subpopulation ( n = 311 ) , median progression-free survival with everolimus was 2027 months ( 95 % CI 1495-2408 ) versus 1308 months ( 1005-1656 ) with placebo ( hazard ratio 066 , 95 % CI 048-091 ; p = 00049 ) ; however , the protocol-specified significance threshold ( p = 00044 ) was not crossed .